Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Weiner

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
Cancer Immunology, Immunotherapy : CII|October 19, 2017
Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in miceJill P Smith, Shangzi Wang, Sandeep Nadella, et al.
The Journal of Biological Chemistry|October 9, 2004
Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding formatLillian S Shahied, Yong Tang, R Katherine Alpaugh, et al.
Cancer Research|August 17, 2002
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal modelJonathan D Cheng, Roland L Dunbrack, Matthildi Valianou, et al.
Oncoimmunology|May 10, 2019
SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent miceReham Ajina, Danielle Zamalin, Annie Zuo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigenYong Tang, Jianlong Lou, R Katherine Alpaugh, et al.
Expert Opinion on Therapeutic Targets|February 25, 2009
Mechanisms of tumor resistance to EGFR-targeted therapiesElizabeth A Hopper-Borge, Rochelle E Nasto, Vladimir Ratushny, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2008
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapyLiat Binyamin, R Katherine Alpaugh, Tracey L Hughes, et al.
Plos One|January 9, 2014
Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAsNarayan Shivapurkar, Louis M Weiner, John L Marshall, et al.
Cancer Immunology Research|October 11, 2014
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicityJoseph C Murray, Dalal Aldeghaither, Shangzi Wang, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 21, 2003
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I reportMelvyn Goldberg, Jeffrey Farma, Craig Lampert, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Cancer Immunology, Immunotherapy : CII|October 19, 2017
Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in miceJill P Smith, Shangzi Wang, Sandeep Nadella, et al.
The Journal of Biological Chemistry|October 9, 2004
Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding formatLillian S Shahied, Yong Tang, R Katherine Alpaugh, et al.
Cancer Research|August 17, 2002
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal modelJonathan D Cheng, Roland L Dunbrack, Matthildi Valianou, et al.
Oncoimmunology|May 10, 2019
SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent miceReham Ajina, Danielle Zamalin, Annie Zuo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigenYong Tang, Jianlong Lou, R Katherine Alpaugh, et al.
Expert Opinion on Therapeutic Targets|February 25, 2009
Mechanisms of tumor resistance to EGFR-targeted therapiesElizabeth A Hopper-Borge, Rochelle E Nasto, Vladimir Ratushny, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2008
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapyLiat Binyamin, R Katherine Alpaugh, Tracey L Hughes, et al.
Plos One|January 9, 2014
Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAsNarayan Shivapurkar, Louis M Weiner, John L Marshall, et al.
Cancer Immunology Research|October 11, 2014
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicityJoseph C Murray, Dalal Aldeghaither, Shangzi Wang, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 21, 2003
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I reportMelvyn Goldberg, Jeffrey Farma, Craig Lampert, et al.
Pageof 14